Expertise in
17
conditions

Dr. Timothy S. Pardee

Hematology
North Carolina Baptist Hospital
1 Medical Ctr Blvd, 
Winston Salem, NC 
Accepting New Patients
Expertise in
17
conditions
North Carolina Baptist Hospital
1 Medical Ctr Blvd, 
Winston Salem, NC 

Overview

Timothy Pardee is a Hematologist practicing medicine in Winston Salem, North Carolina.

Dr. Pardee is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 59 peer reviewed articles and participating in 10 clinical trials. Dr. Pardee is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in NC

Hospital Affiliations

North Carolina Baptist Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AmeriHealth
  • EPO
  • HMO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

North Carolina Baptist Hospital
1 Medical Ctr Blvd, Winston Salem, NC 27103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

An Investigator-Sponsored Randomized Phase II Study of Selinexor in Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients
An Investigator-Sponsored Randomized Phase II Study of Selinexor in Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients
Enrollment Status: Active_not_recruiting
Publish Date: August 20, 2026
Intervention Type: Drug
Study Drugs: Cytarabine, Daunorubicin, Selinexor
Study Phase: Phase 2
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Enrollment Status: Terminated
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Study Phase: Phase 3
A Pilot Study of CPI-613 in Patients With Myelodysplastic Syndrome Who Have Failed Previous Therapy
A Pilot Study of CPI-613 in Patients With Myelodysplastic Syndrome Who Have Failed Previous Therapy
Enrollment Status: Terminated
Publish Date: October 17, 2024
Intervention Type: Drug
Study Phase: Phase 2
An Open Label Study to Evaluate the Feasibility of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
An Open Label Study to Evaluate the Feasibility of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Procedure, Drug
Study Drugs: 6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Mitoxantrone
Study Phase: Phase 1
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: July 29, 2024
Intervention Type: Drug
Study Drug: Uproleselan
Study Phase: Phase 3
A Study of the Metabolic Changes in Leukemia Cells Following Treatment in AML Patients
A Study of the Metabolic Changes in Leukemia Cells Following Treatment in AML Patients
Enrollment Status: Completed
Publish Date: October 20, 2022
Intervention Type: Other
Investigating the Prognostic Importance of Bioelectrical Impedance Phase Angle in Adults Treated for Newly Diagnosed Acute Leukemia
Investigating the Prognostic Importance of Bioelectrical Impedance Phase Angle in Adults Treated for Newly Diagnosed Acute Leukemia
Enrollment Status: Completed
Publish Date: August 13, 2020
Intervention Type: Procedure
Study Phase: Not Applicable
An Open Label, Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
An Open Label, Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: August 14, 2019
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: February 12, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

59 Total Publications

Sarcopenia in Older Adults with Hematologic Malignancies: A Comprehensive Review of Epidemiology, Prognosis, and Interventions.
Sarcopenia in Older Adults with Hematologic Malignancies: A Comprehensive Review of Epidemiology, Prognosis, and Interventions.
Journal: Cancers
Published: December 19, 2025
Similar Doctors
Expertise in
16
conditions
Dr. Matthew J. Wieduwilt
Hematology | Oncology
Expertise in
16
conditions
Dr. Matthew J. Wieduwilt
Hematology | Oncology
Referral may be required

North Carolina Baptist Hospital

1 Medical Ctr Blvd, 
Winston Salem, NC 
 (0.1 miles away)
336-713-5440
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Wieduwilt is a Hematologist and an Oncologist practicing medicine in Winston Salem, North Carolina. Dr. Wieduwilt is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Wieduwilt is currently accepting new patients.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Office

2311 Lewisville Clemmons Rd Fl 2, 
Clemmons, NC 
 (8.6 miles away)
336-713-1717
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rakhee Vaidya is a Hematologist practicing medicine in Clemmons, North Carolina. Dr. Vaidya is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Vaidya is currently accepting new patients.

Expertise in
18
conditions
Dr. Rupali Roy
Hematology
Expertise in
18
conditions
Dr. Rupali Roy
Hematology
Referral may be required

North Carolina Baptist Hospital

1 Medical Ctr Blvd, 
Winston Salem, NC 
 (0.1 miles away)
336-716-2011
Languages Spoken:
English, Bengali
See accepted insurances
Accepting New Patients
Offers Telehealth

Rupali Roy is a Hematologist practicing medicine in Winston Salem, North Carolina. Dr. Roy is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), and Bone Marrow Aspiration. Dr. Roy is currently accepting new patients.

Frequently Asked Questions about Dr. Timothy S. Pardee

How do I make an appointment with Dr. Timothy S. Pardee?

You can book an appointment with Dr. Timothy S. Pardee by calling their office at 336-713-5440. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Timothy S. Pardee a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Timothy S. Pardee is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Timothy S. Pardee specialize in?

While Dr. Timothy S. Pardee is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Leukemia, and Myelodysplastic Syndrome (MDS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Timothy S. Pardee participate in research or clinical trials?

Yes. Dr. Timothy S. Pardee has published 59 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Timothy S. Pardee's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Timothy S. Pardee accept my insurance?

Dr. Timothy S. Pardee accepts most major insurance plans, including Aetna and AmeriHealth. We recommend calling the office directly at 336-713-5440 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pardee's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile